Dear Jonathan,
Jack Ladenson and his group in St Louis have been working on an assay for
FA Binding Protein (FABP) for some years, and there is a group in Japan
which has published papers on the use of FABP. The Japanese study
(presented also at the IFCC Congress in Florence in 1999) has never taken
off for a variety of reasons, mainly reproducibility and the need for
standardization which seems to be lacking. The Ladenson group, which has
been working together with an industrial partner, has actually managed to
isolate an excellent Ab, however they too feel that at present their
product is not likely to succeed in the market.
The main reason for this is that very infrequently does a patient present
so early that the FABP would be the only useful marker. The use of
myoglobin as an early negative marker, and CK-MB followed by Troponin as
the positive markers still seem to be the best combination presently
available (as noted by Ian Godber as well in his reply to you).
Perhaps a quick FABP screen could be used for paramedics arriving at the
scene of a presumed AMI, to give a very early indication for ruling in or
out, but then again the kit would have to be more robust and reliable.
With best wishes,
Oren
At 08:55 18/06/2001 +0100, you wrote:
>I hear this was discussed on Tomorrow's World as a useful marker for
>cardiac damage. (Obviously the future for CPD.) Does anyone have any
>good sources/ reviews/ contacts?
>
>Dr Jonathan Kay
>
>
Prof. Oren Zinder
Department of Clinical Biochemistry
Rambam Medical Center
Haifa, ISRAEL 31096
Tel: +972-4-854-3767
Fax: +972-4-854-2409
email: [log in to unmask]
|